Author Archives: admin


Stem Cell Clinic > Articles by: admin

Global Gene Therapy Market to Garner a Revenue of About USD 6 Billion by 2031 by Growing with a CAGR of ~34% During 2022-2031 – GlobeNewswire

By Gene Therapy Clinics

New York, July 13, 2022 (GLOBE NEWSWIRE) -- According to the World Health Organization (WHO), around 10 million deaths, or nearly 1 in 6 deaths, were caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. If found early and appropriately treated, many tumors (30% to 50%) are curable. According to the American Cancer Society (ACS), 1,918,030 new cancer cases and 609,360 cancer deaths are expected in 2022, with lung cancer as the primary cause of death accounting for about 350 of those fatalities daily in the United States.

In recent research titled Global Gene Therapy Market, Kenneth Research provided a brief overview of market elements including growth drivers, restraint factors, current market trends, and potential for future growth. The influence of COVID-19 and its effects on end-users are both thoroughly examined in the market research report, which covers the forecast period, i.e., 2022-2031. In addition, the research study examines the product portfolios and market expansion plans of the principal competitors. In 2020, according to the World Cancer Research Fund (WCRF), there were 18 million new cases of cancer worldwide. 9.3 million of these instances involved men, while 8.8 million involved women. The growth of the global gene therapy market can be attributed on account of the rising prevalence of cancer cases. Also, the adoption of gene therapies for the treatment of cancer is predicted to grow the market further. For instance, at the University of Pennsylvania, the first trial for testing a CRISPR-created cancer medicine was launched in the United States in 2019.CRISPR is a gene-editing-tool, that can modify any DNA segment within the 3 billion letters of the human genome. The global gene therapy market is expected to gather around USD 6 billion in revenue by 2031 and grow with a CAGR of ~34% over the forecast period. Get A Sample Copy of This Report @ https://www.kennethresearch.com/sample-request-10070542

The global gene therapy market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. On the back of rapid rising cancer incidence rates, and the availability of high disposable income, the market in North America is predicted to experience significant expansion over the course of the forecast period. For instance, the Cancer Facts & Figures 2021 by the American Cancer Society, the study estimates that 1.9 million new instances of cancer were diagnosed and 608,570 cancer deaths in the United States in 2021. Also, an increase in the demand for gene-therapy-related R&D activities further helps the growth of the market. According to the World Bank Data, the domestic general government healthcare expenditure in the U.S. was 5,552.60 IN 2019 whereas in Canada the domestic general health care expenditure was 3,873.70 in 2019. Thus, a rise in government health care support is expected to expand the gene therapy-related R&D activities and further aid on to improve the market in the region. On the other hand, the global gene therapy market in the Asia Pacific region is anticipated to experience the greatest CAGR throughout the forecast period owing to the growing population in the region and increased approval and availability of gene therapy products. According to the World Bank data, the total population of China was 1.41 billion in 2020 whereas, India had 1.38 billion people in 2020. As the population grows, the likelihood of contracting a disease increases. Additionally, it is anticipated that increased government efforts to upgrade the health care infrastructure and rising healthcare costs in that region are expected to expand the industry. Also, the health care expenditure in Japan in 2019 was 10.74% whereas, in China, the GDP was 5.35%. In addition to that, the domestic general government health expenditure per capita for Japan was 3,846.54 in 2019 and China was 492.72 in 2019. Thus, growing health care expenditure and government support in health care expansion are further expected for the growth of the market in the region.

Browse to access In-depth research report on Gene Therapy Market with detailed charts and figures: https://www.kennethresearch.com/report-details/gene-therapy-market/10070542

The study further incorporates Y-O-Y Growth, demand & supply and forecasts future opportunities in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC[Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia Pacific(China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia Pacific), Middle East and Africa(Israel, GCC[Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of the Middle East and Africa). The global gene therapy market is segmented by indication into cancer, metabolic disorders, eye disorders, cardiovascular diseases, and others. Among that the cancer segment is predicted to hold the largest share over the forecast period. On account of the growing widespread presence of cancer cases, the growth of the market can be accredited. The estimated number of new cases of cancer patients in India was around 11,57,294 cases which had risen to 13,24,413 total cases in 2020. In addition to that, the total number of cancer patients was 1,708,921 in 2018 in the U.S., according to the Centers for Disease Control and Prevention (CDC) which got increased to an estimated rate of 1.8 million new cases in 2020. The statistical studies exhibit an increasingly widespread of the disease worldwide which is expected to drive the growth of the segment. Gene therapies are used to treat a variety of malignancies, including those of the brain, lung, breast, pancreatic, liver, prostate, bladder, head & neck, skin, and ovary. For instance, according to the World Cancer Research Fund (WCRF), the most common cancers around the world were breast and lung cancers, accounting to 12.5% and 12.2% respectively of all new cases that were expected to be diagnosed in 2020. Also, there were 1.9 million new instances of colorectal cancer, accounting for 10.7% of all cancer cases in 2020.

Get a Sample PDF of Global Gene Therapy Market @ https://www.kennethresearch.com/sample-request-10070542

The global gene therapy market is segmented by end-user into pharma & biotech, and academia. Numerous ongoing researches and studies have been conducted in the pharma and biotech sector which is anticipated to account for the growth of the segment. For instance, based on a study by PhRMA, there were 289 gene therapies done in clinical development by biopharmaceutical companies in 2018 which had increased to 362 gene therapies in 2020. Also, 6 diseases were already being treated using gene therapy, whereas 362 cell and gene therapies were in the development stage in 2020. In addition to that, 9 cell or gene therapy products have been approved by U.S. Food and Drug Administration (FDA) as of February 2020; they are used to treat cancer, eye conditions, and uncommon inherited diseases.

The global gene therapy market is also segmented on the basis of technology and application.

Global Gene Therapy Market, Segmentation by Technology:

Global Gene Therapy Market, Segmentation by Application:

Enquiry before Buying This Report @ https://www.kennethresearch.com/sample-request-10070542

Some of the well-known leaders in the global gene therapy market that are included in our report are Kineta, Inc., Orchard Therapeutics plc, SIBIONO, Questex, CRISPR Therapeutics, Editas Medicine, and others.

Browse More Related Reports:

Disposable Syringes Market Segmentation by Type (General/Conventional, Safety, and Pre-Filled Syringes); by Syringe Tip (Luer-Lock, Slip, Eccentric, and Catheter Syringe Tips); by Application (Immunization, and Therapeutic Injections, and Others); by End-User (Hospitals, Diagnostic Laboratories, Blood Banks, Pharmaceutical Companies, and Others)-Global Demand Analysis & Opportunity Outlook 2021-2031

Immunoassays in R&D Market Segmentation by Application (Cancer Research, Infectious Diseases, Autoimmune Diseases, Endocrinology, and Others); by End-Use (Academic Laboratories & Institutions, Biotechnology & Pharmaceutical Companies, and Others); and by Product & Services (Analyzers, Software & Services, and Kits & Reagents)-Global Demand Analysis & Opportunity Outlook 2031

Lancet Market Segmentation by Type (Push Button Safety, Pressure Activated Safety, Personal, and Side Button Safety); by Application (Glucose Testing, Hemoglobin Testing, and Coagulation Testing); and by End Users (Homecare, Hospitals & Clinics, Blood Banks, and Others)-Global Demand Analysis & Opportunity Outlook 2031

Anticholinergic Drugs Market Segmentation by Product Type (Natural, Semi-Synthetic Compound, and Synthetic Compound); by Route of Administration (Parenteral, Topical, and Oral); by Application (Muscle Spasm, Parkinsons Disease, Irritable Bowel Syndrome, Chronic Obstructive Pulmonary Disease, and Overactive Bladder); and by Channel of Distribution (Hospitals, Retail Pharmacies, and Online Pharmacies)-Global Demand Analysis & Opportunity Outlook 2031

Global Vaginal Slings Market Segmentation by End-Use (Clinics, Hospitals, and Ambulatory Surgical Centers); and by Slings Type (Conventional, and Advanced Vaginal Slings)-Demand Analysis & Opportunity Outlook 2031

About Kenneth Research

Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@kennethresearch.com

U.S. Phone: +1 313 462 0609

Web: https://www.kennethresearch.com/

Original post:
Global Gene Therapy Market to Garner a Revenue of About USD 6 Billion by 2031 by Growing with a CAGR of ~34% During 2022-2031 - GlobeNewswire

CRISPR Technology Highlights Genes That Contribute to the Development of Emphysema and COPD – Boston Medical Center

By Induced Pluripotent Stem Cells

BOSTON Researchers from the Center for Regenerative Medicine at Boston Medical Center and Boston University School of Medicine used variants of CRISPR to understand the functions of the genes that cause emphysema and chronic obstructive pulmonary disease (COPD). Published in Science Advances, researchers discovered functional consequences by turning off the expression of the gene that contributes to the pathogenesis of these diseases.

This is the first time that CRISPRi and CRISPRa have been applied in human induced pluripotent stem cells to understand the functional role of these genes, says Andrew Wilson, MD, a pulmonologist at Boston Medical Center and associate professor of medicine at Boston University School of Medicine. It gets us closer to understanding how inherited factors help contribute to susceptibility to emphysema.

COPD and emphysema is the third leading cause of death worldwide, creating a significant burden of disease. Emphysema is a complex genetic disease caused by a mutation or variant in a number of genes that contribute to making some individuals more susceptible to disease than others. Genome-wide association studies (GWAS) have implicated variants in or near a growing number of genes, but understanding their functions and how they potentially contribute to the development of COPD and emphysema is quite limited.

There have been no new significant pharmacological agents developed to help treat the large number of patients afflicted with COPD or emphysema worldwide, says Rhiannon Werder, MD, a postdoctoral fellow at the Center for Regenerative Medicine at Boston Medical Center and Boston University School of Medicine. Our hope is that this study will help in the understanding of the genetics of the disease, improve our understanding of how the disease occurs at a cellular level, and support the development of new therapies to treat these conditions.

Researchers devised a system using variants of CRISPR to either turn off expression of a gene of interest using CRISPR interference (CRISPRi) or overexpress a gene of interest using CRISPR activation (CRISPRa) in induced pluripotent stem cells (iPSCs). Researchers grew these cells in a dish and differentiated them to generate cells that reside in the lung. The cell type studied is called the type 2 alveolar epithelial cell, a progenitor cell for the alveolus the alveolus is the part of the lung where gas exchange occurs and is the structure that is damaged in emphysema. So by understanding how GWAS genes affect type 2 cells, researchers can start to understand how these might contribute to diseases that affect these cells, like emphysema.

Once type 2 cells were generated, researchers then used CRISPRi to turn off expression of nine different GWAS genes and analyzed them to see how the cells were affected, especially their ability to proliferate, something that they need to be able to do in response to injury like that which occurs in emphysema. Researchers noticed that turning off one particular gene, desmoplakin (DSP), caused the cells to increase their proliferation and increased their expression of genes associated with cellular maturation. Researchers found that cells in which DSP expression was turned off before smoke exposure turned off expression of cell junction genes to a greater degree than in controls. These were also better at forming new colonies, a measure of progenitor function, than controls. Researchers then looked in mice that had DSP deleted from their lung epithelial cells, compared to control mice with normal DSP. Researchers found that the type 2 cells in the DSP deletion mice were more proliferative following injury, consistent with findings in human iPSC-derived type 2 cells.

DSP appears to modulate the proliferative capacity of type 2 cells at baseline and following injuries that are relevant to human disease, such as smoke exposure. Lower levels of DSP expression increase the proliferative capacity of type 2 cells in the system, potentially making them better able to respond to an injury. In contrast, higher levels of expression as found in cells containing the variant associated with COPD risk by GWAS appear to make the cells less proliferative after smoke exposure, potentially explaining how this gene contributes to disease.

See the original post:
CRISPR Technology Highlights Genes That Contribute to the Development of Emphysema and COPD - Boston Medical Center

The ‘Benjamin Button’ effect: Scientists can reverse aging in mice. The goal is to do the same for humans – KITV Honolulu

By Induced Pluripotent Stem Cells

In molecular biologist David Sinclair's lab at Harvard Medical School, old mice are growing young again.

Using proteins that can turn an adult cell into a stem cell, Sinclair and his team have reset aging cells in mice to earlier versions of themselves. In his team's first breakthrough, published in late 2020, old mice with poor eyesight and damaged retinas could suddenly see again, with vision that at times rivaled their offspring's.

"It's a permanent reset, as far as we can tell, and we think it may be a universal process that could be applied across the body to reset our age," said Sinclair, who has spent the last 20 years studying ways to reverse the ravages of time.

"If we reverse aging, these diseases should not happen. We have the technology today to be able to go into your hundreds without worrying about getting cancer in your 70s, heart disease in your 80s and Alzheimer's in your 90s." Sinclair told an audience at Life Itself, a health and wellness event presented in partnership with CNN.

"This is the world that is coming. It's literally a question of when and for most of us, it's going to happen in our lifetimes," Sinclair told the audience.

"His research shows you can change aging to make lives younger for longer. Now he wants to change the world and make aging a disease," said Whitney Casey, an investor who is partnering with Sinclair to create a do-it-yourself biological age test.

While modern medicine addresses sickness, it doesn't address the underlying cause, "which for most diseases, is aging itself," Sinclair said. "We know that when we reverse the age of an organ like the brain in a mouse, the diseases of aging then go away. Memory comes back; there is no more dementia.

"I believe that in the future, delaying and reversing aging will be the best way to treat the diseases that plague most of us."

In Sinclair's lab, two mice sit side by side. One is the picture of youth, the other gray and feeble. Yet they are brother and sister, born from the same litter -- only one has been genetically altered to age faster.

If that could be done, Sinclair asked his team, could the reverse be accomplished as well? Japanese biomedical researcher Dr. Shinya Yamanaka had already reprogrammed human adult skin cells to behave like embryonic or pluripotent stem cells, capable of developing into any cell in the body. The 2007 discovery won the scientist a Nobel Prize, and his "induced pluripotent stem cells," soon became known as "Yamanaka factors."

However, adult cells fully switched back to stem cells via Yamanaka factors lose their identity. They forget they are blood, heart and skin cells, making them perfect for rebirth as "cell du jour," but lousy at rejuvenation. You don't want Brad Pitt in "The Curious Case of Benjamin Button" to become a baby all at once; you want him to age backward while still remembering who he is.

Labs around the world jumped on the problem. A study published in 2016 by researchers at the Salk Institute for Biological Studies in La Jolla, California, showed signs of aging could be expunged in genetically aged mice, exposed for a short time to four main Yamanaka factors, without erasing the cells' identity.

But there was a downside in all this research: In certain situations, the altered mice developed cancerous tumors.

Looking for a safer alternative, Sinclair lab geneticist Yuancheng Lu chose three of the four factors and genetically added them to a harmless virus. The virus was designed to deliver the rejuvenating Yamanaka factors to damaged retinal ganglion cells at the back of an aged mouse's eye. After injecting the virus into the eye, the pluripotent genes were then switched on by feeding the mouse an antibiotic.

"The antibiotic is just a tool. It could be any chemical really, just a way to be sure the three genes are switched on," Sinclair said. "Normally they are only on in very young developing embryos and then turn off as we age."

Amazingly, damaged neurons in the eyes of mice injected with the three cells rejuvenated, even growing new axons, or projections from the eye into the brain. Since that original study, Sinclair said his lab has reversed aging in the muscles and brains of mice and is now working on rejuvenating a mouse's entire body.

"Somehow the cells know the body can reset itself, and they still know which genes should be on when they were young," Sinclair said. "We think we're tapping into an ancient regeneration system that some animals use -- when you cut the limb off a salamander, it regrows the limb. The tail of a fish will grow back; a finger of a mouse will grow back."

That discovery indicates there is a "backup copy" of youthfulness information stored in the body, he added.

"I call it the information theory of aging," he said. "It's a loss of information that drives aging cells to forget how to function, to forget what type of cell they are. And now we can tap into a reset switch that restores the cell's ability to read the genome correctly again, as if it was young."

While the changes have lasted for months in mice, renewed cells don't freeze in time and never age (like, say, vampires or superheroes), Sinclair said. "It's as permanent as aging is. It's a reset, and then we see the mice age out again, so then we just repeat the process.

"We believe we have found the master control switch, a way to rewind the clock," he added. "The body will then wake up, remember how to behave, remember how to regenerate and will be young again, even if you're already old and have an illness."

Studies on whether the genetic intervention that revitalized mice will do the same for people are in early stages, Sinclair said. It will be years before human trials are finished, analyzed and, if safe and successful, scaled to the mass needed for a federal stamp of approval.

While we wait for science to determine if we too can reset our genes, there are many other ways to slow the aging process and reset our biological clocks, Sinclair said.

"The top tips are simply: Focus on plants for food, eat less often, get sufficient sleep, lose your breath for 10 minutes three times a week by exercising to maintain your muscle mass, don't sweat the small stuff and have a good social group," Sinclair said.

What controls the epigenome? Human behavior and one's environment play a key role. Let's say you were born with a genetic predisposition for heart disease and diabetes. But because you exercised, ate a plant-focused diet, slept well and managed your stress during most of your life, it's possible those genes would never be activated. That, experts say, is how we can take some of our genetic fate into our own hands.

Cutting back on food -- without inducing malnutrition -- has been a scientifically known way to lengthen life for nearly a century. Studies on worms, crabs, snails, fruit flies and rodents have found restricting calories "delay the onset of age-related disorders" such as cancer, heart disease and diabetes, according to the National Institute on Aging. Some studies have also found extensions in life span: In a 1986 study, mice fed only a third of a typical day's calories lived to 53 months -- a mouse kept as a pet may live to about 24 months.

Studies in people, however, have been less enlightening, partly because many have focused on weight loss instead of longevity. For Sinclair, however, cutting back on meals was a significant factor in resetting his personal clock: Recent tests show he has a biological age of 42 in a body born 53 years ago.

"I've been doing a biological test for 10 years now, and I've been getting steadily younger for the last decade," Sinclair said. "The biggest change in my biological clock occurred when I ate less often -- I only eat one meal a day now. That made the biggest difference to my biochemistry."

Sinclair incorporates other tools into his life, based on research from his lab and others. In his book "Lifespan: Why We Age and Why We Don't Have To," he writes that little of what he does has undergone the sort of "rigorous long-term clinical testing" needed to have a "complete understanding of the wide range of potential outcomes." In fact, he added, "I have no idea if this is even the right thing for me to be doing."

With that caveat, Sinclair is willing to share his tips: He keeps his starches and sugars to a minimum and gave up desserts at age 40 (although he does admit to stealing a taste on occasion). He eats a good amount of plants, avoids eating other mammals and keeps his body weight at the low end of optimal.

He exercises by taking a lot of steps each day, walks upstairs instead of taking an elevator and visits the gym with his son to lift weights and jog before taking a sauna and a dip in an ice-cold pool. "I've got my 20-year-old body back," he said with a smile.

Speaking of cold, science has long thought lower temperatures increased longevity in many species, but whether it is true or not may come down to one's genome, according to a 2018 study. Regardless, it appears cold can increase brown fat in humans, which is the type of fat bears use to stay warm during hibernation. Brown fat has been shown to improve metabolism and combat obesity.

Sinclair takes vitamins D and K2 and baby aspirin daily, along with supplements that have shown promise in extending longevity in yeast, mice and human cells in test tubes.

One supplement he takes after discovering its benefits is 1 gram of resveratrol, the antioxidant-like substance found in the skin of grapes, blueberries, raspberries, mulberries and peanuts.

He also takes 1 gram of metformin, a staple in the arsenal of drugs used to lower blood sugars in people with diabetes. He added it after studies showed it might reduce inflammation, oxidative damage and cellular senescence, in which cells are damaged but refuse to die, remaining in the body as a type of malfunctioning "zombie cell."

However, some scientists quibble about the use of metformin, pointing to rare cases of lactic acid buildup and a lack of knowledge on how it functions in the body.

Sinclair also takes 1 gram of NMN, or nicotinamide mononucleotide, which in the body turns into NAD+, or nicotinamide adenine dinucleotide. A coenzyme that exists in all living cells, NAD+ plays a central role in the body's biological processes, such as regulating cellular energy, increasing insulin sensitivity and reversing mitochondrial dysfunction.

When the body ages, NAD+ levels significantly decrease, dropping by middle age to about half the levels of youth, contributing to age-related metabolic diseases and neurodegenerative disorders. Numerous studies have shown restoring NAD+ levels safely improves overall health and increases life span in yeast, mice and dogs. Clinical trials testing the molecule in humans have been underway for three years, Sinclair said.

"These supplements, and the lifestyle that I am doing, is designed to turn on our defenses against aging," he said. "Now, if you do that, you don't necessarily turn back the clock. These are just things that slow down epigenetic damage and these other horrible hallmarks of aging.

"But the real advance, in my view, was the ability to just tell the body, 'Forget all that. Just be young again,' by just flipping a switch. Now I'm not saying that we're going to all be 20 years old again," Sinclair said.

"But I'm optimistic that we can duplicate this very fundamental process that exists in everything from a bat to a sheep to a whale to a human. We've done it in a mouse. There's no reason I can think of why it shouldn't work in a person, too."

& 2022 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

Continued here:
The 'Benjamin Button' effect: Scientists can reverse aging in mice. The goal is to do the same for humans - KITV Honolulu

Growing Prevalence & Recurrence Of Rheumatoid Arthritis Is Expected To Growth Of The Rheumatoid Arthritis Stem Cell Therapy Market Designer Women…

By Stem Cell Treatment

The Global Rheumatoid Arthritis Stem Cell Therapy Market is replete with new growth opportunities and expansion avenues. There has been an increase in the use of products and services falling under the ambit of Rheumatoid Arthritis Stem Cell Therapy, giving a thrust to the growth of the global Rheumatoid Arthritis Stem Cell Therapy market. The unprecedented use of these products can be attributed to the increasing paying capacity of the masses.

Furthermore, in the absence of robust or utilitarian alternatives, the demand within the global Rheumatoid Arthritis Stem Cell Therapy market is projected to reach new heights of recognition. It is worthwhile to mention that the global Rheumatoid Arthritis Stem Cell Therapy market is treading along a lucrative pathway due to favorable government legislations.

To get in-depth insights Request for Brochure here https://www.factmr.com/connectus/sample?flag=B&rep_id=1001

The COVID-19 pandemic has changed narratives related to growth and expansion across several key industries. Therefore, the Rheumatoid Arthritis Stem Cell Therapy market is also battling the cons of supply chain disruptions and procurement issues. Over the course of the next quarter, market players could be investing in new technologies to recover from the shocks of the pandemic.

The global market for rheumatoid arthritis stem cell therapy is highly fragmented. Examples of some of the key players operating in the global rheumatoid arthritis stem cell therapy market include Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, TiGenix and others.

Through the latest research report on Rheumatoid Arthritis Stem Cell Therapy market, the readers get insights on:

Share Your Requirements & Get Customized Reports: https://www.factmr.com/connectus/sample?flag=RC&rep_id=1001

Tentatively, the global rheumatoid arthritis stem cell therapy market can be segmented on the basis of treatment type, application, end-user, and geography.

Based on treatment type, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on application, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on the distribution channel, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on geography, the global rheumatoid arthritis stem cell therapy market can be segmented into:

The study further identifies major manufacturing trends, technologies that will be commercialized

Reasons to choose a Fact.MR:

For In-depth Analysis & Business Strategy, Buy a Copy of this Report: https://www.factmr.com/checkout/1001

About Fact. MR

Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and well be an able research partner.

Contact:US Sales Office : 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E-Mail:sales@factmr.com

Corporate Headquarter:Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates

Read the rest here:
Growing Prevalence & Recurrence Of Rheumatoid Arthritis Is Expected To Growth Of The Rheumatoid Arthritis Stem Cell Therapy Market Designer Women...

Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL – Cancer Network

By Stem Cell Treatment

Catherine S. Diefenbach, MD, spoke about refining understanding of CAR T-cell therapies after the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma.

Lisocabtagene maraleucel (liso-cel; Breyanzi) was recently approved for the second-line treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma not otherwise specified; high-grade B-cell lymphoma; primary mediastinal LBCL; and grade 3B follicular lymphoma.1 CancerNetwork spoke with Catherine S. Diefenbach, MD, director of both Hematology and Translational Research and the Clinical Lymphoma Program of Perlmutter Cancer Center at NYU Langone Health, about data from the phase 3 TRANSFORM trial (NCT03575351) that led to the approval and how the indication for this and other similar therapies may be expanded in the future with better understand regarding how to tailor the therapy.2

There are a couple of steps that are going to be important. One is to get a better idea of who benefits so we can tailor this therapy to the patients who are going to benefit the most. We need to get better at understanding the mechanisms of relapse and nonresponse to CAR T-cell therapy so that we [avoid subjecting] patients to this toxic therapy who are unlikely to benefit and/or design a next-generation CAR T-cell treatment that is going to allow more patients to have a durable response and be cured than what is currently approved. We need to get better at managing the toxicity of CAR T cells because this is still a fairly toxic therapy, and design next-generation CAR T cells that are less toxic. We need to get better about improving access so more patients can have access to CAR T cells. There are still many issues around insurance and payments for commercial CAR T cells. From a drug development, a clinical, and a public health standpoint, theres still much work that we can do to optimize this therapy.

This is an exciting time in lymphoma. We have a new therapy that was approved initially in the third line thats now moving to the second line and other exciting therapies that are nearing approval. We have more ways than ever to cure patients with lymphoma or extend the lives of people with incurable lymphoma. The challenge going forward is going to understand who benefits from which therapy and understand how to optimize response for all patients with these exciting therapies that we now have. This is an absolutely wonderful and transformative development.

Read more:
Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL - Cancer Network

Global Lupus Market is Expected to Reach USD 4.3 Billion With CAGR of 12.41% By Forecast 2027 Says Maximize Market Research (MMR) – Digital Journal

By Stem Cell Treatment

The Global Lupus Market Is Estimated To Grow To USD 4.3 Billion With A CAGR Of 12.41 Percent By 2027.

TheGlobal Lupus Markethas gained traction in the last decade, and from 2022 to 2027, it is expected to grow at a compound annual growth rate (CAGR) of 4.3 percent. Market revenue will have increased to USD 4.3 billion by the end of 2027, up from USD 1.88 billion in 2020.

Global Lupus Market Scope and Dynamics:

Due to factors such rising healthcare costs, a growing female population, rapid urbanisation, supportive government measures, rising rates of SLE disease, etc., the industry has been expanding over the past few years. Different groups and the government are doing a number of actions to educate people about SLE. Several research institutions are offering medicines and treatments to SLE patients with government funding. Government-funded trials for several novel medications are now underway. The Centers for Disease Control and Prevention (CDC) in the US frequently publish SLE disease statistics and alert the public to the diseases serious side effects, particularly in the female population.

The market is anticipated to expand quickly over the forecast period as a result of a number of current trends, including an increase in clinical trials, the use of stem cell therapy, increased public awareness, etc. One of the most promising emerging areas of medicine for the treatment of Global Lupus, particularly for patients who do not respond well to more conventional forms of treatment, may be stem cell therapy. Stem cell therapy is becoming more popular since it is a cutting-edge method for treating Global Lupus, which will boost the growth of the Global Lupus market.

One of the key elements anticipated to restrain the growth of the global Global Lupus therapeutic market over the forecast period is the negative effects of medications used to treat the disease. For instance, almost all patients receiving treatment for SLE report one or more side effects such nausea, vomiting, bone toxicity, and other symptoms, according to a paper published in the peer-reviewed, open access journal Global Lupus Science and Medicine in March 2018.

Request Free Sample:@https://www.maximizemarketresearch.com/request-sample/65753

Global Lupus Market Region Insights:

Geographically, the North America are expected to lead the Global Lupus market due to the growing need for better treatment choices, the diseases increasing prevalence, government initiatives for it, and the availability of reimbursement. In addition, the regions developed healthcare system and easy access to biologics are anticipated to support market growth.

The Global Lupus market is expected to place Europe in second place. The growth of R&D initiatives and the increased incidence of Global Lupus in the area are both credited with driving the market in this region.

China, Japan, South Korea, India, Australia, and the rest of Asia-Pacific make up the Asia-Pacific Global Lupus market. Due to the rising Global Lupus prevalence, the growing healthcare industry, and the increasing geographical development of major market participants, the Asia-Pacific region is anticipated to have the quickest growth.

Global Lupus Market Segmentation:

By Technique:

By Product:

By End-User:

By Region:

Key Players in Global Lupus Market:

To Get a Detailed Report Summary and Research Scope of the Global Lupus Market Click here:@https://www.maximizemarketresearch.com/market-report/global-lupus-market/65753/

About Maximize Market Research:

Maximize Market Research provides syndicated and custom B2B and B2C business and market research on high-growth emerging technologies, opportunities, and threats for companies in the chemical, internet of things, food and beverage, healthcare, pharmaceuticals, electronics and communications, aerospace, and defense. Maximize Market Research is best positioned to assess, estimate, and anticipate market size along with the competitive landscape of industries as businesses across the globe are battling to keep up with the pace of changing market, along with changing industrial, and technical conditions.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

[emailprotected]

Read the rest here:
Global Lupus Market is Expected to Reach USD 4.3 Billion With CAGR of 12.41% By Forecast 2027 Says Maximize Market Research (MMR) - Digital Journal

Academic-industry partnership aims to lower the cost of cultivated meat – University of Toronto

By Stem Cell Treatment

When the University of TorontosMichael Gartongot a call from Myo Palate a company that is producing meat without raising whole animals he knew it was the opportunity hed been waiting for.

My research has always been focused on health care and medical applications, says Garton, an assistant professor in the Institute of Biomedical Engineering in the Faculty of Applied Science & Engineering.

But environmental issues are something I really care about something we all care about. Given the impact that agriculture has on the environment, I knew this would be a great way to make a difference.

Myo Palate is looking tap the synthetic biology expertise of Garton and his team in an effort to reduce the cost of growing muscle cells. The collaborationis funded by a grant provided jointly by Genome Ontario and the Canadian Food Innovation Network.

This is an exciting opportunity to collaborate with Dr. Garton and utilize cutting-edge synthetic biology techniques to reduce the cost of growing muscle cells, says Frank Yu, co-founder of Myo Palate.

While our initial products will not contain genetic modifications, we think that this will be a game changer for the future.

Gartonscurrent medical researchinvolvesdesigning customized stem cells, derived from a patients own tissues, that could be used to treat certain diseases or conditions.

For example, one challenge we are interested in is neurological diseasessuch as multiple sclerosis or ALS, which are caused or amplified by chronic inflammation of nerve tissue, says Garton.

We can take stem cells from a patient and program them to specifically detect chronic inflammation and to release anti-inflammatory molecules in response. We could then re-implant those cells back into the body.

Because the anti-inflammatory molecules are released only where and when they are needed, this approach known asex vivogene therapy could reduce the side effects associated with treatment via traditional drugs.

Using this knowledge to create cultivated meat that is, animal cells grown outside a living animal may not seem like an intuitive leap to make, but Garton says that there are plenty of parallels.

In our work, we face the challenge of getting our stem cells to grow and differentiate into the types of tissues we want to make, he says.

Producers of cultivated meat will be doing much of the same thing. And because their cells will be consumed as food, rather than implanted into a patient, there are fewer obstacles in the overall process, which in a way makes it slightly easier.

But the challenges of creating cultivated meat go well beyond whether or not it is technically possible economics are also critically important. Cultivated meat is not yet cost-competitive with raising whole animals, which is one of the major factors limiting its widespread adoption.

Unless we can get the cost down, its just not going to fly, says Garton. What were hoping is that our expertise in synthetic biology can reduce or even remove the need for some of the more costly inputs.

One example is growth factors, which are specialized biochemicals that signal what kind of environment a given cell is growing in. Their presence or absence determines what type of tissue a stem cell will grow into: for example, skin, nerves or muscle.

In the case of cultivated meat, the goal is typically to produce myocytes, or large muscle cells. While growth factors that result in this type of tissue can be readily purchased, their relatively high cost is a major hurdle to producing cultivated meat at a competitive price.

Garton and his team hope that their research can result in stem cells that require lower amounts of these growth factors, or even none at all.

Were testing lots of different ways of approaching this challenge, and were also automating the process so we can do it in a high-throughput way, says Garton.

Were developing machine learning methods that can sort through the data to find out whats working and whats not, and what will most likely be successful in the next iteration.

Garton says he is excited about the opportunity to make an impact in a fast-growing field.

Its going to be a very long time before we have a stem cell that automatically grows into a real muscle in the lab with minimal inputs, he says.But in terms of putting the foundational pieces and core building blocks in place to achieve that, I think were going to be able to deliver some real insights relatively quickly.

Read the original:
Academic-industry partnership aims to lower the cost of cultivated meat - University of Toronto

Does Chemotherapy Have Cognitive and Emotional Side Effects? – Healthline

By Stem Cell Treatment

Chemotherapy has transformed cancer care, but its benefits come with side effects. Chemo brain is the name some people give to the brain fog and fuzziness that can result from these lifesaving treatments.

Chemotherapy works by destroying fast-reproducing cancer cells. But it can kill other healthy cells along the way, including certain brain cells. The destruction of brain cells can impact your emotional state and ability to think, leading to memory and concentration problems, among other concerns.

This article will explore what types of cognitive and emotional changes you might expect from chemotherapy, what factors increase your risk for these symptoms, and what you can do to treat them.

Various emotional and cognitive symptoms can occur during chemotherapy, and they should be categorized separately. Even though they both apply to your brain and can be considered mental side effects, emotion and cognition are different.

Cognition refers broadly to the intellectual processes of absorbing, analyzing, and using information. Emotions are our feelings and responses to experiences, environments, and relationships. For example, trouble focusing is a cognitive side effect, whereas irritability is an emotional one.

Lets go over some of the most common chemotherapy side effects in both categories.

Cognitive changes are usually the most noticeable impacting daily functioning, work or school performance, and personal relationships.

Confusion or delirium is the most common of these symptoms, affecting roughly 57 to 85 percent of people undergoing chemotherapy, compared to 15 to 30 percent of people hospitalized for other medical reasons.

Cognitive changes can look different depending on the individual but commonly include:

In addition to chemo, other factors can contribute to emotional stress as part of a cancer diagnosis. The emotional impacts of chemo can look like shifts in mood, depression or anxiety. Personality changes are common, too.

These can be linked to chemotherapy treatments, the disease process, and coping with a cancer diagnosis.

Learn more about the emotional impacts of a cancer diagnosis and cancer treatment.

There are several reasons why chemotherapy can impact your mental and emotional health.

One reason is that chemo medications cross the blood-brain barrier, causing inflammation. Brain shrinkage, or a loss of neurons, has been observed as a result of both cancer and chemotherapy.

Cognitive changes can also be heightened by complications of cancer treatment or other medical conditions. Chronic pain and lack of sleep or appetite from chemotherapy treatments can have profound negative life impacts.

This can affect your energy and strength levels, making it hard to focus or regulate your emotions.

Cancers spread to the brain can also directly affect cognitive and emotional functioning. This can be separate from, or in addition to, chemo.

While chemotherapy aims to slow or stop the spread of cancer, increased changes in mental status and cognition can also be signs of metastasis, or that the cancer is spreading.

Your doctor may also want to rule out intolerances or reactions to your chemotherapy treatment.

Treating cancer requires an individualized and multidisciplinary approach. Often, a rehabilitation plan is involved in helping you cope with or heal from the effects of chemotherapy and other intensive treatments, including any surgeries.

Your doctor may want to adjust your chemotherapy regimen depending on your side effects.

Cognitive rehabilitation is sometimes included in a chemotherapy plan and offers activities or exercises to help keep your mind sharp and focused during treatment.

The American Cancer Society suggests that exercise and meditation can go a long way in reducing the mental toll of chemotherapy and other cancer treatments.

Also, talk therapy, including cognitive behavioral therapy (CBT), may help you process the complex emotions arising from a cancer diagnosis and treatment.

Talk therapies can help you develop coping techniques that may help you manage fatigue, confusion, and any depression or anxiety you are experiencing due to chemotherapy.

There are particular cancer and chemotherapy medications that can increase the chances of confusion, delirium, and other cognitive changes in some people. Your doctor should review any risks of a potential treatment option with you when designing your chemo regimen.

Consider coming to your appointment prepared with questions about what risk of physical and mental impacts chemo may cause. Ensure your doctor knows all medications you are currently taking to avoid adverse reactions.

If you choose to move forward with treatment, your doctor may be able to help you find ways to preserve your thinking abilities should chemo affect them, or at the very least learn to cope with the changes.

There are certain risk factors that may increase your chance of experiencing mental side effects during chemotherapy.

Besides taking specific medications or having brain cancer, this can include having:

Chemotherapy can effectively manage cancer and bring about remission. But the medications for chemotherapy are strong and highly toxic to other cells and systems in your body. This treatment can cause unpleasant physical, mental, and emotional symptoms.

The physical effects of chemotherapy like nausea and hair loss are well-known, but substantial mental and cognitive changes can also happen with this therapy. Chemo brain refers to the fatigue, confusion, and overall brain fog some people experience.

Talk with your doctor about the specific risks versus benefits for your type of cancer, stage, and prescribed chemotherapy regimen. Your medical team should be able to help you with therapies and strategies that can help you cope with the emotional and cognitive toll of cancer and chemotherapy.

The rest is here:
Does Chemotherapy Have Cognitive and Emotional Side Effects? - Healthline

Crowdfunder launched to pay for life-changing treatment abroad for Brora mum battling MS issues: ‘If you can help me get a chance of a new life, I…

By Stem Cell Treatment

Residents in Sutherland are being urged to support a crowdfunder to meet the cost of private treatment abroad for a local woman diagnosed with a potentially life-threatening illness.

A fundraising drive has been launched in the hope of sending 41-year-old Kirsteen Mackay, a Durness native now living in Brora, to Mexico for treatment which she is unable to access on the NHS.

Within hours of the crowdfunder going live this week, it had reached 20 per cent of its 57,000 target.

On her social media page, Ms Mackay, who is experiencing a complication linked to multiple sclerosis, said: The last few years have been a struggle for me and this last year has been the worst as I have had failed treatments with awful side effects.

I just want to thank those who have helped me and continue to do so, as I would not have made it this far without you.

I know money is tight for everyone, but if you can help me get a chance of a new life, I will be forever grateful.

The caring, generous and fun-loving mum, who has a six-year-old son Ruaraidh and who runs Kirsteens Kollection, a decor service for all occasions, was diagnosed in 2018 with relapsing-remitting multiple sclerosis (RRMS).

Jade McAlea, who set up the crowdfunder said: Kirsteens RRMS is very active and medication is crucial to keeping symptoms or the progression of symptoms under control.

But Ms Mackay was recently dealt a devastating blow when she was told she had tested positive for John Cunningham virus (JC).

The virus is common and usually harmless - in most people it is dormant and does not directly cause health problems. However it can trigger a life-threatening condition called multifocal leukoencephalopathy (PML).

A few of the medications that doctors use to treat MS can reactivate the dormant virus and lead to PML.

This means that treatment for RRMS has been reduced to one option, which can be used for a year, said Ms McAlea. Unfortunately this treatment is also linked to patients being in a high-risk category for developing PML.

The NHS has been wonderful so far in supporting Kirsteen with effective treatment for her RRMS diagnosis, but with this most recent development of JC, the treatment option and timeline is simply time she does not have to spare due to the risk of symptoms exacerbating..

Her most hopeful outcome is to undergo treatment which is available privately in Mexico, but the cost of this treatment means it is an option out of reach. That is where we believe people can make the lifesaving difference.

The procedure Ms Mackay hopes to undergo at Clinica Ruiz in Puebla, is Haematopoietic Stem Cell Transplantation (HSTC), an intense chemotherapy treatment where the patients own stem cells are used to reboot their immune system.

Ms Mackay is not eligible for HSTC on the NHS because she is not a wheelchair user, her family said. The treatment is not available privately in Scotland and there are long waiting lists to have it privately in England.

Ms McAlea continued: We have every faith in our community that we can all come together at such a devastating time for Kirsteen and her family.

No help is too big or small and with all your support, we can provide Kirsteen with the hope of a healthy, happy future.

Click here to donate.

Read the original post:
Crowdfunder launched to pay for life-changing treatment abroad for Brora mum battling MS issues: 'If you can help me get a chance of a new life, I...

Updates in the Treatment of HER2+ mBC from ASCO 2022 – OncLive

By Stem Cell Treatment

Vijayakrishna Gadi, MD, PhD: I would say that, in all of this HER2 disease, sadly if you have HER2-postivie breast cancer, although weve done a tremendous job extending the lives of those patients, ultimately the majority of those patients still die. We cant rest on our laurels, and weve got to keep innovating in this area. There are many, many new molecules and entities that are being considered, and Im excited to test those. Weve heard about a number of them at this 2022 ASCO [American Society of Clinical Oncology Annual] Meeting, and obviously in its early days, and we hope that those will come in.

The other emphasis or way to look at it is, now that we have all these tools, what can we put together in a safe manner that could still be effective for our patients? Ill highlight a few trials in this regard. One is looking at combining T-DM1 [trastuzumab emtansine] with tucatinib; the so-called HER2CLIMB-02 study [NCT03975647]. Thats a trial thats ongoing. We hope that itll accrue quickly, and then well have answers, but heres a generally well-tolerated antibody-drug conjugate being combined with tucatinib, which has the CNS [central nervous system]-penetrating ability. You can see where Im going with this with covering our bases above the neck but also below the neck. That could be one option. If its successful, its a randomized phase 3 trial, so it could be a new standard of care depending on what we learn from that.

Theres a DESTINY-Breast trial looking in a phase 2 setting at patients with CNS metastases and the combination of tucatinib. That study is still looking at safety initially, and then hopefully we will be able to expand out to efficacy cohorts. Itll be a smaller study, but it may give us a signal that then we can formally test in a larger randomized control trial. Thats another option. Then lastly, [we are] looking at combinations with drugs like tucatinib and conventional things like chemotherapy: trastuzumab and pertuzumab. Although its not from the metastatic setting, when we try to do that in the I-SPY2 trial [NCT01042379] in the preoperative setting, that was actually too toxic. It was effective, but it was too toxic and should not be pursued at this time, so weve got to go back to the drawing board on that one. Its not all wins. We are going to look at these combinations, but certainly, with the tools we have, we may be able to push the needle quite a bit by just combining them. The adage is, If you cant beat them, join them, so thats what were seeing in this space.

At2022 ASCO, a standing ovation talk claimed there is a new standard of care, which was the DESTINY-Breast04 trial [NCT0373402].. To refresh everybodys memory just in case, DESTINY-Breast04 was a trial that looked at patients with HER2-low diseaseIm going to talk about the definition of HER2-low in a minuteand using trastuzumab deruxtecan vs physicians choice chemotherapy options. In that trial, [there was a] running away nice separation of the curves for this HER2-low population favoring the trastuzumab deruxtecan. Fortunately, [there were] not a lot of new emergent [adverse] effects or toxicities that make us take pause in this. [They were] very familiar in terms of toxicities and were in many cases favorable compared to chemotherapy. [It is] very easy to say, Yeah, this could be a new standard of care.

Now Im Monday-morning quarterbacking on this molecule in this study. First off, what is HER2-low? We know that some cancers, when they express HER2 strongly, we call it HER2+. Those are cancers where the driver is the HER2 gene. Those are cancers that we can target with all our conventional therapies that weve had access to: trastuzumab, pertuzumab, tucatinib, neratinib, and all these molecules become relevant. For these, HER2, IHC [immunohistochemistry] 2-positive and below, this is not a driver. Its a target of convenience. The expression is necessary to get the antibody-drug conjugate to the location, internalize the chemotherapy, and then kill the cancer cell. Fortunately, with trastuzumab deruxtecan, you have this wonderful thing called bystander killing. The chemotherapy leaks out and kills the neighboring cells as well. Even if you have low or heterogeneous expression of the HER2 target as a target of convenience, its localizing the chemotherapy to where we need it to be, and that chemotherapy is very potent. That has now formally been tested in a randomized controlled [phase] 3 trial and that hypothesis is true. This is an effective molecule for that disease space.

As we try to integrate this, a lot of these patients have hormone receptorpositive disease. I suspect were going to continue to tackle that because those therapies are well tolerated compared to chemotherapies and even antibody-drug conjugates. Once those stop working for our patients, its very easy to think how well be reaching for trastuzumab deruxtecan for those patients. Within that trial, they also studied what we call triple-negative disease thats HER2-low. For those patients, there are now a couple of options. We have sacituzumab govitecan, which is formally evaluated in a robust dataset and [has been] shown to benefit those patients, but we also have this very active molecule, trastuzumab deruxtecan. If you notice how Im saying these words, govitecan [and] deruxtecan, they end in the same terminal 5 letters. These are all Topo1 inhibitors, so there may be cross-resistance. Our ability to use these drugs one after the other isnt assumed. We have to test that formally to see if thats even possible. I think, in the triple-negative space, [its] a little murky. For those HER2-low [cases], you have a couple of options, and for those that dont make HER2 at any level, the so-called HER2-0 [cases], I think sacituzumab govitecan might be the choice for those patients.

Thank you very much for listening to my ramblings about HER2-positive metastatic breast cancer. Its a rapidly changing field. If you took boards just a few years ago, youve go5t to know a lot going forward to make sure you do well on the boards in the future. Fortunately, for our patients, this innovation is really making an impact for them, so thank you to the patients whove also participated on these studies to help the patients coming down the pipe.

Transcript has been edited for clarity.

See the article here:
Updates in the Treatment of HER2+ mBC from ASCO 2022 - OncLive

→←